L-779976
L-779976 is a compound with bradykinin agonist activity. Injection into the amygdala and septum of the rat brain can produce anxiolytic effects. Its bradykinin agonist activity has been verified by relevant experiments.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 214770-19-1
- Fòrmula: C33H43N7O3
- Peso molecular:585.74
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Actividad biológica
Descripciòn
Chemical Information
-
No. CAS 214770-19-1
-
Peso molecular 585.74
-
Fòrmula C33H43N7O3
-
SMILES
O=C1N(C2CCN(CC2)C(N[C@@H](C(NC[C@H]3C[C@H](CCC3)CN)=O)[C@H](C4=CNC5=CC=CC=C45)C)=O)C6=CC=CC=C6N1
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocolo
-
How to Select the Route of Administration for Mammals
Route-of-administration selection in mammals is a pharmacokinetic, pharmacodynamic, formulation, animal-welfare, and translational decision, not a default technical choice. The selected route should match the study goal: intravenous dosing is most useful when complete systemic exposure and rapid onset are required, oral dosing is most translational for orally intended medicines but is affected by absorption and first-pass metabolism, subcutaneous or intramuscular dosing can provide slower systemic exposure, and intraperitoneal dosing can be useful in rodent proof-of-concept studies but may have limited clinical translation. Published route-comparison studies show that the same compound can produce different exposure, onset, bioavailability, tissue distribution, and tolerability depending on route; therefore, route choice should be supported by pilot pharmacokinetic or pharmacodynamic evidence when the literature is insufficient. Unresolved questions include how to standardize route sel
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)